Do analysts prefer MBAI or PTHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, MBAI or PTHL?

Check-Cap has higher earnings, but lower revenue than Pheton. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Check-Cap N/A N/A $4.14M -$2.77 N/A Pheton $305.22K 7.33 -$660K N/A N/A

Is MBAI or PTHL more profitable?

Company Net Margins Return on Equity Return on Assets Check-Cap N/A N/A N/A Pheton N/A N/A N/A

Do analysts prefer QNRX or PTHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, QNRX or PTHL?

Pheton has higher revenue and earnings than Quoin Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quoin Pharmaceuticals N/A N/A -$15.81M -$29.56 N/A Pheton $305.22K 7.33 -$660K N/A N/A

Is QNRX or PTHL more profitable?

Pheton's return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Quoin Pharmaceuticals N/A -489.85% -221.29% Pheton N/A N/A N/A

Do analysts recommend VVOS or PTHL?

Vivos Therapeutics presently has a consensus price target of $2.80, indicating a potential upside of 385.02%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Vivos Therapeutics is more favorable than Pheton. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, VVOS or PTHL?

Pheton has lower revenue, but higher earnings than Vivos Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vivos Therapeutics $17.44M 0.46 -$21.17M -$2.14 N/A Pheton $305.22K 7.33 -$660K N/A N/A

Do analysts rate SINT or PTHL?

Sintx Technologies presently has a consensus target price of $9.33, indicating a potential upside of 322.32%. Given Sintx Technologies' stronger consensus rating and higher probable upside, equities analysts plainly believe Sintx Technologies is more favorable than Pheton. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sintx Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, SINT or PTHL?

Pheton has lower revenue, but higher earnings than Sintx Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sintx Technologies $1.02M 9.36 -$10.36M -$5.07 N/A Pheton $305.22K 7.33 -$660K N/A N/A

Do analysts rate PTHL or NXL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, PTHL or NXL?

Pheton has higher revenue and earnings than Nexalin Technology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pheton $305.22K 7.33 -$660K N/A N/A Nexalin Technology $275.58K 30.20 -$8.22M -$0.47 N/A

Pheton (PTHL) Competitors

$0.34 -0.06 (-16.03%)

As of 06/12/2026

Compare

PTHL vs. MBAI, QNRX, VVOS, SINT, and NXL

Should you buy Pheton stock or one of its competitors? MarketBeat compares Pheton with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pheton include Check-Cap (MBAI), Quoin Pharmaceuticals (QNRX), Vivos Therapeutics (VVOS), Sintx Technologies (SINT), and Nexalin Technology (NXL). These companies are all part of the "medical equipment" industry.

How does Pheton compare to Check-Cap?

Check-Cap (NASDAQ:MBAI) and Pheton (NASDAQ:PTHL) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Check-Cap has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Pheton has a beta of 5.4, indicating that its stock price is 440% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Check-Cap has higher earnings, but lower revenue than Pheton.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Check-Cap	N/A	N/A	$4.14M	-$2.77	N/A
Pheton	$305.22K	7.33	-$660K	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Check-Cap	N/A	N/A	N/A
Pheton	N/A	N/A	N/A

1.1% of Check-Cap shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Check-Cap had 3 more articles in the media than Pheton. MarketBeat recorded 3 mentions for Check-Cap and 0 mentions for Pheton. Check-Cap's average media sentiment score of 1.21 beat Pheton's score of 0.00 indicating that Check-Cap is being referred to more favorably in the media.

Company	Overall Sentiment
Check-Cap	Positive
Pheton	Neutral

Summary

Check-Cap beats Pheton on 5 of the 7 factors compared between the two stocks.

How does Pheton compare to Quoin Pharmaceuticals?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Pheton has higher revenue and earnings than Quoin Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
Pheton	$305.22K	7.33	-$660K	N/A	N/A

Quoin Pharmaceuticals has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market. Comparatively, Pheton has a beta of 5.4, meaning that its stock price is 440% more volatile than the broader market.

Pheton's return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
Pheton	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Quoin Pharmaceuticals had 2 more articles in the media than Pheton. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 0 mentions for Pheton. Quoin Pharmaceuticals' average media sentiment score of 1.43 beat Pheton's score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Quoin Pharmaceuticals	Positive
Pheton	Neutral

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 13.5% of Quoin Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Quoin Pharmaceuticals beats Pheton on 6 of the 11 factors compared between the two stocks.

How does Pheton compare to Vivos Therapeutics?

Vivos Therapeutics (NASDAQ:VVOS) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Vivos Therapeutics presently has a consensus price target of $2.80, indicating a potential upside of 385.02%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Vivos Therapeutics is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pheton has a net margin of 0.00% compared to Vivos Therapeutics' net margin of -127.70%. Pheton's return on equity of 0.00% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
Pheton	N/A	N/A	N/A

In the previous week, Vivos Therapeutics had 13 more articles in the media than Pheton. MarketBeat recorded 13 mentions for Vivos Therapeutics and 0 mentions for Pheton. Vivos Therapeutics' average media sentiment score of 0.50 beat Pheton's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Vivos Therapeutics	Neutral
Pheton	Neutral

Pheton has lower revenue, but higher earnings than Vivos Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44M	0.46	-$21.17M	-$2.14	N/A
Pheton	$305.22K	7.33	-$660K	N/A	N/A

26.4% of Vivos Therapeutics shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Vivos Therapeutics has a beta of 6.1, indicating that its stock price is 510% more volatile than the broader market. Comparatively, Pheton has a beta of 5.4, indicating that its stock price is 440% more volatile than the broader market.

Summary

Vivos Therapeutics beats Pheton on 9 of the 14 factors compared between the two stocks.

How does Pheton compare to Sintx Technologies?

Sintx Technologies (NASDAQ:SINT) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

Pheton has a net margin of 0.00% compared to Sintx Technologies' net margin of -1,058.60%. Pheton's return on equity of 0.00% beat Sintx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-1,058.60%	-366.49%	-115.04%
Pheton	N/A	N/A	N/A

In the previous week, Sintx Technologies had 2 more articles in the media than Pheton. MarketBeat recorded 2 mentions for Sintx Technologies and 0 mentions for Pheton. Sintx Technologies' average media sentiment score of 1.16 beat Pheton's score of 0.00 indicating that Sintx Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Sintx Technologies	Positive
Pheton	Neutral

Sintx Technologies presently has a consensus target price of $9.33, indicating a potential upside of 322.32%. Given Sintx Technologies' stronger consensus rating and higher probable upside, equities analysts plainly believe Sintx Technologies is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sintx Technologies has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Pheton has a beta of 5.4, suggesting that its stock price is 440% more volatile than the broader market.

Pheton has lower revenue, but higher earnings than Sintx Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$1.02M	9.36	-$10.36M	-$5.07	N/A
Pheton	$305.22K	7.33	-$660K	N/A	N/A

18.4% of Sintx Technologies shares are owned by institutional investors. 4.1% of Sintx Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Sintx Technologies beats Pheton on 9 of the 14 factors compared between the two stocks.

How does Pheton compare to Nexalin Technology?

Pheton (NASDAQ:PTHL) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Pheton has higher revenue and earnings than Nexalin Technology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305.22K	7.33	-$660K	N/A	N/A
Nexalin Technology	$275.58K	30.20	-$8.22M	-$0.47	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nexalin Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pheton has a net margin of 0.00% compared to Nexalin Technology's net margin of -3,018.12%. Pheton's return on equity of 0.00% beat Nexalin Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
Nexalin Technology	-3,018.12%	-191.88%	-166.43%

In the previous week, Nexalin Technology had 5 more articles in the media than Pheton. MarketBeat recorded 5 mentions for Nexalin Technology and 0 mentions for Pheton. Nexalin Technology's average media sentiment score of 0.85 beat Pheton's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Pheton	Neutral
Nexalin Technology	Positive

0.6% of Nexalin Technology shares are held by institutional investors. 25.3% of Nexalin Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Pheton has a beta of 5.4, indicating that its stock price is 440% more volatile than the broader market. Comparatively, Nexalin Technology has a beta of 3.8, indicating that its stock price is 280% more volatile than the broader market.

Summary

Pheton beats Nexalin Technology on 6 of the 11 factors compared between the two stocks.

Get Pheton News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTHL vs. The Competition

Export

Metric	Pheton	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.24M	$8.68B	$6.48B	$12.34B
Dividend Yield	N/A	1.71%	2.67%	5.67%
P/E Ratio	N/A	23.79	23.96	24.58
Price / Sales	7.33	22.82	536.40	168.09
Price / Cash	N/A	13.73	27.48	37.92
Price / Book	0.36	5.59	10.47	6.78
Net Income	-$660K	$174.80M	$3.56B	$337.32M
7 Day Performance	21.43%	1.93%	0.91%	2.01%
1 Month Performance	9.32%	10.14%	1.86%	3.88%
1 Year Performance	-98.03%	6.28%	25.73%	32.23%

Pheton Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTHL Pheton	N/A	$0.34 -16.0%	N/A	-98.0%	$2.24M	$305.22K	N/A	11	Gap Down
MBAI Check-Cap	0.9471 of 5 stars	$1.33 -5.0%	N/A	N/A	$10.20M	N/A	N/A	80	Short Interest Decrease
QNRX Quoin Pharmaceuticals	1.5765 of 5 stars	$5.06 +2.2%	N/A	-49.9%	$9.94M	N/A	N/A	4	Analyst Forecast Short Interest Decrease Gap Down
VVOS Vivos Therapeutics	3.7368 of 5 stars	$0.64 -8.8%	$2.80 +338.3%	-73.3%	$9.73M	$17.44M	N/A	160	Positive News
SINT Sintx Technologies	3.5987 of 5 stars	$2.07 -3.7%	$9.33 +350.9%	-35.2%	$9.29M	$1.02M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTHL) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pheton (PTHL) Competitors

PTHL vs. MBAI, QNRX, VVOS, SINT, and NXL

How does Pheton compare to Check-Cap?

Summary

How does Pheton compare to Quoin Pharmaceuticals?

Summary

How does Pheton compare to Vivos Therapeutics?

Summary

How does Pheton compare to Sintx Technologies?

Summary

How does Pheton compare to Nexalin Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTHL vs. The Competition

Pheton Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pheton (PTHL) Competitors

PTHL vs. MBAI, QNRX, VVOS, SINT, and NXL

How does Pheton compare to Check-Cap?

Which has more volatility and risk, MBAI or PTHL?

Do analysts prefer MBAI or PTHL?

Which has stronger earnings & valuation, MBAI or PTHL?

Is MBAI or PTHL more profitable?

Do institutionals & insiders hold more shares of MBAI or PTHL?

Does the media refer more to MBAI or PTHL?

Summary

How does Pheton compare to Quoin Pharmaceuticals?

Which has stronger earnings and valuation, QNRX or PTHL?

Which has more risk and volatility, QNRX or PTHL?

Is QNRX or PTHL more profitable?

Do analysts prefer QNRX or PTHL?

Does the media favor QNRX or PTHL?

Do insiders and institutionals hold more shares of QNRX or PTHL?

Summary

How does Pheton compare to Vivos Therapeutics?

Do analysts recommend VVOS or PTHL?

Is VVOS or PTHL more profitable?

Does the media prefer VVOS or PTHL?

Which has stronger valuation & earnings, VVOS or PTHL?

Do insiders & institutionals have more ownership in VVOS or PTHL?

Which has more risk and volatility, VVOS or PTHL?

Summary

How does Pheton compare to Sintx Technologies?

Is SINT or PTHL more profitable?

Does the media favor SINT or PTHL?

Do analysts rate SINT or PTHL?

Which has more volatility & risk, SINT or PTHL?

Which has stronger valuation and earnings, SINT or PTHL?

Do institutionals & insiders have more ownership in SINT or PTHL?

Summary

How does Pheton compare to Nexalin Technology?

Which has preferable valuation and earnings, PTHL or NXL?

Do analysts rate PTHL or NXL?

Is PTHL or NXL more profitable?

Does the media refer more to PTHL or NXL?

Do institutionals and insiders have more ownership in PTHL or NXL?

Which has more volatility and risk, PTHL or NXL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTHL vs. The Competition

Pheton Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools